MACK(Delisted)
MerrimackยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MACK
Merrimack Pharmaceuticals, Inc.
A biopharmaceutical company that develops pharmaceuticals and companion diagnostics for the treatment of cancer and other serious diseases
One Broadway, 14th Floor, Cambridge, MA 02142
--
Merrimack Pharmaceuticals, Inc. The company was incorporated in the Commonwealth of Massachusetts in 1993 and reorganized in Delaware in October 2010. Is a biopharmaceutical company engaged in the discovery, development and preparation of commercialized innovative drugs (including novel companion diagnostic therapies). The company has six clinical-stage tumor targeting product candidates (MM-398, MM-121, MM-111, MM-302, MM-151 and MM-141) and multiple product candidates in preclinical development, and is committed to driving the discovery of more drug candidates. Its research and development work is driven by network biology, which is a special discipline for biomedical research based on biology.
Company Financials
EPS
MACK has released its 2023 Q3 earnings. EPS was reported at -0.02, versus the expected 0, missing expectations. The chart below visualizes how MACK has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
